Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

Future Oncol. 2015;11(21):2853-6. doi: 10.2217/fon.15.210. Epub 2015 Sep 25.

Authors

Vito Amoroso¹, Fausto Petrelli², Rebecca Pedersini^{1

3}, Edda Lucia Simoncini³, Philippe Clézardin⁴, Sandro Barni², Alfredo Berruti¹

Affiliations

¹ Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia at Spedali Civili Hospital, Brescia, Italy.
² Medical Oncology Unit, Azienda Ospedaliera Treviglio Caravaggio, Treviglio, Italy.
³ Breast Unit, Spedali Civili Hospital, Brescia, Italy.
⁴ INSERM, Research Unit U1033, University of Lyon-1, Faculty of Medicine Lyon-Est (domaine Laennec), Lyon, France.

PMID: 26403833
DOI: 10.2217/fon.15.210

No abstract available

Keywords: bisphosphonates; breast cancer; disseminated tumor cells; osteoblastic niche; parathyroid hormone.

Publication types

Editorial
Meta-Analysis
Review

MeSH terms

Bone Density Conservation Agents / classification
Bone Density Conservation Agents / pharmacology
Bone Density Conservation Agents / therapeutic use*
Bone Resorption / drug therapy
Bone Resorption / etiology
Breast Neoplasms / complications
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Chemotherapy, Adjuvant
Clodronic Acid / pharmacology
Clodronic Acid / therapeutic use
Diphosphonates / classification
Diphosphonates / pharmacology
Diphosphonates / therapeutic use*
Female
Humans
Neoplasm Staging
Treatment Outcome

Substances

Bone Density Conservation Agents
Diphosphonates
Clodronic Acid